CompletedPhase 2NCT00300768
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
Studying Onchocerciasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medicines Development for Global Health
- Principal Investigator
- Nicholas Opoku, MDOnchocerciasis Chemotherapy Research Center, Hohoe, Ghana
- Intervention
- 2 mg moxidectin(drug)
- Enrollment
- 172 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2006 – 2009
Study locations (1)
- Onchocerciasis Chemotherapy Research Center, Hohoe, Volta Region, Ghana
Collaborators
World Health Organization
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00300768 on ClinicalTrials.govOther trials for Onchocerciasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06350851Development of a New Rapid Diagnostic Test to Support Onchocerciasis EliminationBioaster
- ACTIVE NOT RECRUITINGPHASE2NCT05180461Emodepside Phase II Trial for Treatment of OnchocerciasisDrugs for Neglected Diseases
- ACTIVE NOT RECRUITINGPHASE3NCT03876262Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for OnchocerciasisMedicines Development for Global Health